In line with these results, the combination of a survivin peptide with anti-CTLA-4 was associated with the generation of survivin-specific T cells and long-term survival of mice in a therapeutic setting, but not in a prophylactic experiment (i.e., before tumor challenge) [75]. This evidence concerns the gene CTLA4 and neoplasm.